In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
News|Podcasts|October 7, 2026
ACT Brief: FDA Transparency Roadmap, Radiopharmaceutical Trial Operations, and AI-Powered Enrollment Prediction
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In a
new transparency roadmap , the FDA outlined fiscal year 2026 milestones and fiscal year 2027 priorities across five areas: CRL disclosure, investigational and marketing application lifecycle transparency, new approach methodologies and novel biomarkers, patient-centered labeling, and compliance and inspectional records. The agency also formalized a memorandum of understanding with the SEC in August 2026 to establish regular information sharing between the two agencies on FDA-regulated products and firms for use in regulatory and enforcement activities. - In a
new contributed article , Kavita Gaadhe examined why radiopharmaceutical trials are exposing a broader challenge for clinical development: scientific innovation can advance only as fast as the infrastructure, data, and cross-functional decisions required to deliver it. With the radiopharmaceuticals market projected to grow eight to ten percent annually to nearly 14 billion dollars by 2033, trial success increasingly rests on three interconnected pillars beyond the molecular design. - In a
new podcast from Pharmaceutical Executive , Matt Walz, CEO of Trialbee, explored how AI is delivering practical gains in enrollment planning and discussed its future potential in making clinical development's biggest bottleneck more predictable. He outlined how AI applied to internal workflows differs fundamentally from AI-driven decision-making based on real-world data, where bias concerns require different governance and oversight approaches.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
In today's ACT Brief, we examine what patient-site relationships need beyond easier technology, how to build defensible rare disease evidence from scratch, and how real-world data and AI improve enrollment screening accuracy.
Trending on Applied Clinical Trials Online
1
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
2
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
3
Mixed Outsourcing Models Are Spreading. Is Sponsor Oversight Keeping Up?
4
Beyond the Molecule: Why Radiopharmaceutical Trials Require a New Operating Model
5